CTL 8004Alternative Names: CTL-8004
Latest Information Update: 11 Oct 2006
At a glance
- Originator Dendreon Corporation; Johnson & Johnson Pharmaceutical Research & Development
- Mechanism of Action Immunomodulators; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 16 Jul 2002 Phase-I clinical trials in Cancer in USA(unspecified route)
- 17 Oct 2000 New profile
- 17 Oct 2000 Preclinical development for Cancer in USA (Unknown route)